Ascentage Pharma has listed on the Nasdaq Global Market, becoming the first 18A company to achieve a dual listing on the US stock market.   Ascentage Pharma offered 7,325,000 American depositary shares (ADS) at $17.25 per ADS. The proceeds from the offering are expected to be approximately $126.4 million.  The company aims to address unmet medical […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!